날리딕스산

날리딕스산
날리딕스산 구조식 이미지
카스 번호:
389-08-2
한글명:
날리딕스산
동의어(한글):
날리딕스산
상품명:
Nalidixic acid
동의어(영문):
neggram;Nalidixic acid BP93.CH.P.95;1,4-DIHYDRO-1-ETHYL-7-METHYL-4-OXO-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID;cybis;nalix;NOGRAM;uropan;uroneg;uroman;negram
CBNumber:
CB1194283
분자식:
C12H12N2O3
포뮬러 무게:
232.24
MOL 파일:
389-08-2.mol
MSDS 파일:
SDS

날리딕스산 속성

녹는점
227-229 °C (lit.)
끓는 점
374.4°C (rough estimate)
밀도
1.2243 (rough estimate)
굴절률
1.6660 (estimate)
저장 조건
2-8°C
용해도
클로로포름 에 용해됨: 20mg/mL, 투명
물리적 상태
가루
산도 계수 (pKa)
pKa 6.11± 0.02(Approximate)
색상
흰색에서 밝은 노란색
수용성
0.1G/L(23℃)
Merck
14,6359
BRN
750515
안정성
안정적인. 강한 산화제와 호환되지 않습니다.
CAS 데이터베이스
389-08-2(CAS DataBase Reference)
EPA
Nalidixic acid (389-08-2)
안전
  • 위험 및 안전 성명
  • 위험 및 사전주의 사항 (GHS)
위험품 표기 Xn
위험 카페고리 넘버 63-42/43-40-20/21/22-22
안전지침서 22-36/37-45-24-36
WGK 독일 2
RTECS 번호 QN2885000
F 고인화성물질 8-10-23
HS 번호 29339190
유해 물질 데이터 389-08-2(Hazardous Substances Data)
독성 LD50 in mice (mg/kg): 3300 orally; 500 s.c.; 176 i.v. (Lesher, 1962)
기존화학 물질 KE-13602
그림문자(GHS): GHS hazard pictogramsGHS hazard pictograms
신호 어: Warning
유해·위험 문구:
암호 유해·위험 문구 위험 등급 범주 신호 어 그림 문자 P- 코드
H302 삼키면 유해함 급성 독성 물질 - 경구 구분 4 경고 GHS hazard pictograms P264, P270, P301+P312, P330, P501
H351 암을 일으킬 것으로 의심됨 (노출되어도 암을 일으키지 않는다는 결정적인 증거가 있는 노출경로가 있다면 노출경로 기재) 발암성 물질 구분 2 경고 P201, P202, P281, P308+P313, P405,P501
예방조치문구:
P202 모든 안전 조치 문구를 읽고 이해하기 전에는 취급하지 마시오.
P264 취급 후에는 손을 철저히 씻으시오.
P264 취급 후에는 손을 철저히 씻으시오.
P270 이 제품을 사용할 때에는 먹거나, 마시거나 흡연하지 마시오.
P280 보호장갑/보호의/보안경/안면보호구를 착용하시오.
P301+P312 삼켜서 불편함을 느끼면 의료기관(의사)의 진찰을 받으시오.
P308+P313 노출 또는 접촉이 우려되면 의학적인 조치· 조언를 구하시오.
NFPA 704
1
2 0

날리딕스산 MSDS


1,4-Dihydro-1-ethyl-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid

날리딕스산 C화학적 특성, 용도, 생산

화학적 성질

Crystalline Powder

용도

Nalidixic acid(NegGram) is a synthetic 1,8-naphthyridine antimicrobial agent with a limited bacteriocidal spectrum. It is an inhibitor of the A subunit of bacterial DNA gyrase. Evidence exists that the active metabolite, hydroxynalidixic acid, binds stron

정의

ChEBI: A monocarboxylic acid comprising 1,8-naphthyridin-4-one substituted by carboxylic acid, ethyl and methyl groups at positions 3, 1, and 7, respectively.

Antimicrobial activity

It displays good activity in vitro against a wide range of Enterobacteriaceae.

일반 설명

Cream-colored powder.

공기와 물의 반응

Insoluble in water.

건강위험

SYMPTOMS: Ingestion of Nalidixic acid may cause nausea, vomiting, abdominal pain, allergic reactions and possible liver damage.

화재위험

Flash point data for Nalidixic acid are not available, but Nalidixic acid is probably combustible.

Pharmaceutical Applications

A 1,8 naphthyridone derivative available for oral administration.

Pharmacokinetics

Oral absorption: >90%
Cmax 1 g oral: c. 25 mg/L
Plasma half-life:c.1.5h
Volume of distribution :0.4 L/kg
Plasma protein binding: 93%
The plasma concentrations achieved after oral administration vary widely. In infants with acute shigellosis, absorption is much impaired by diarrhea. Administration with an alkaline compound leads to higher plasma concentrations, partly as the result of enhanced solubility (nalidixic acid is much more soluble at higher pH) and absorption and partly because of reduced tubular reabsorption.
It is rapidly metabolized, principally to the hydroxy acid, which is bacteriologically active, and glucuronide conjugates, which are not. The entire administered dose appears in the urine over a 24 h period. Elimination is reduced by probenecid. In the presence of renal impairment there is little accumulation of the active compound because it continues to be metabolized. However, elimination of metabolites is progressively delayed as renal function declines. About 4% of a dose appears in the feces.

Clinical Use

1-Ethyl-1,4-dihydro-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid (NegGram) occurs as a pale buff crystalline powder that is sparingly soluble in water and ether but solublein most polar organic solvents.Nalidixic acid is useful in the treatment of urinary tractinfections in which Gram-negative bacteria predominate.The activity against indole-positive Proteus spp. is particularlynoteworthy, and nalidixic acid and its congeners representimportant alternatives for the treatment of urinary tractinfections caused by strains of these bacteria resistant toother agents. Nalidixic acid is rapidly absorbed, extensivelymetabolized, and rapidly excreted after oral administration.The 7-hydroxymethyl metabolite is significantly more activethan the parent compound. Further metabolism of theactive metabolite to inactive glucuronide and 7-carboxylicacid metabolites also occurs. Nalidixic acid possesses at1/2elim of 6 to 7 hours. It is eliminated, in part, unchanged inthe urine and 80% as metabolites.

부작용

Adverse reactions are generally those common to all quinolones: gastrointestinal tract and CNS disturbances and skin rashes, including eruptions related to photosensitivity. About half of the reported CNS reactions involve visual disturbances, hallucinations or disordered sensory perception. Severe excitatory states, including acute psychoses and convulsions, are usually observed in patients receiving high dosages. The drug should be avoided in patients with psychiatric disorders or epilepsy.
Acute intracranial hypertension has been observed in children, some of whom have also manifested cranial nerve palsies. Hemorrhage has occurred in patients who were also receiving warfarin, presumably due to displacement of the anticoagulant from its protein binding sites by the nalidixic acid. Hemolytic anemia has been described several times in infants with or without glucose-6-phosphate dehydrogenase deficiency; in adults, death has occurred from autoimmune hemolytic anemia. Arthralgia and severe metabolic acidosis have rarely been reported.

Safety Profile

Poison by intravenous and intraperitoneal routes. Moderately toxic by ingestion and subcutaneous routes. An experimental teratogen. Human systemic effects: convulsions, hyperglycemia, sweating, and blood changes in children. Experimental reproductive effects.Questionable carcinogen with experimental carcinogenic and tumorigenic data. Human mutation data reported. Used as an antibacterial agent and urinary tract antiseptic. When heated to decomposition it emits toxic fumes of NOx.

Purification Methods

Nalidixic acid crystallises from H2O or EtOH as a pale buff powder. It is soluble at 23o in CHCl3 (3.5%), toluene (0.16%), MeOH (0.13%), EtOH (0.09%), H2O (0.01%) and Et2O (0.01%). It inhibits nucleic acid and protein synthesis in yeast. [Lesher et al. J Med & Pharm Chem 5 1063 1962.]

날리딕스산 준비 용품 및 원자재

원자재

준비 용품


날리딕스산 공급 업체

글로벌( 405)공급 업체
공급자 전화 이메일 국가 제품 수 이점
Hebei Yanxi Chemical Co., Ltd.
+8617531190177
peter@yan-xi.com China 6000 58
Capot Chemical Co.,Ltd.
571-85586718 +8613336195806
sales@capotchem.com China 29797 60
Shanghai Daken Advanced Materials Co.,Ltd
+86-371-66670886
info@dakenam.com China 15957 58
Henan Tianfu Chemical Co.,Ltd.
+86-0371-55170693 +86-19937530512
info@tianfuchem.com China 21689 55
career henan chemical co
+86-0371-86658258
sales@coreychem.com China 29914 58
Chongqing Chemdad Co., Ltd
+86-023-61398051 +8613650506873
sales@chemdad.com China 39916 58
CONIER CHEM AND PHARMA LIMITED
+8618523575427
sales@conier.com China 49391 58
Shaanxi Dideu Medichem Co. Ltd
18192627656
1012@dideu.com China 2931 58
TargetMol Chemicals Inc.
+1-781-999-5354 +1-00000000000
marketing@targetmol.com United States 19892 58
Hubei Ipure Biology Co., Ltd
+8613367258412
ada@ipurechemical.com China 10326 58

날리딕스산 관련 검색:

Copyright 2019 © ChemicalBook. All rights reserved